Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
42.81
+1.45 (3.51%)
At close: Feb 2, 2026, 4:00 PM EST
42.79
-0.02 (-0.05%)
After-hours: Feb 2, 2026, 6:21 PM EST
Exelixis Revenue
Exelixis had revenue of $597.76M in the quarter ending September 30, 2025, with 10.79% growth. This brings the company's revenue in the last twelve months to $2.29B, up 9.93% year-over-year. In the year 2024, Exelixis had annual revenue of $2.17B with 18.49% growth.
Revenue (ttm)
$2.29B
Revenue Growth
+9.93%
P/S Ratio
5.17
Revenue / Employee
$1,994,959
Employees
1,147
Market Cap
11.52B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.17B | 338.49M | 18.49% |
| Dec 31, 2023 | 1.83B | 219.15M | 13.60% |
| Dec 31, 2022 | 1.61B | 176.09M | 12.27% |
| Dec 31, 2021 | 1.43B | 447.43M | 45.31% |
| Dec 31, 2020 | 987.54M | 19.76M | 2.04% |
| Dec 31, 2019 | 967.78M | 113.95M | 13.35% |
| Dec 31, 2018 | 853.83M | 401.35M | 88.70% |
| Dec 31, 2017 | 452.48M | 261.02M | 136.34% |
| Dec 31, 2016 | 191.45M | 154.28M | 415.05% |
| Dec 31, 2015 | 37.17M | 12.06M | 48.03% |
| Dec 31, 2014 | 25.11M | -6.23M | -19.87% |
| Dec 31, 2013 | 31.34M | -16.11M | -33.96% |
| Dec 31, 2012 | 47.45M | -242.19M | -83.62% |
| Dec 31, 2011 | 289.64M | 104.59M | 56.52% |
| Dec 31, 2010 | 185.05M | 33.29M | 21.93% |
| Dec 31, 2009 | 151.76M | 33.90M | 28.76% |
| Dec 31, 2008 | 117.86M | 4.39M | 3.87% |
| Dec 31, 2007 | 113.47M | 14.80M | 15.00% |
| Dec 31, 2006 | 98.67M | 22.71M | 29.90% |
| Dec 31, 2005 | 75.96M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.16B |
| BioMarin Pharmaceutical | 3.09B |
| Bio-Techne | 1.22B |
| Ionis Pharmaceuticals | 966.96M |
| Arrowhead Pharmaceuticals | 829.45M |
| Ascendis Pharma | 758.59M |
| Madrigal Pharmaceuticals | 740.64M |
| Axsome Therapeutics | 561.26M |
EXEL News
- 11 hours ago - Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer - Business Wire
- 4 days ago - Exelixis: Stock Likely To Go Higher On A Possible Key FDA Approval - Seeking Alpha
- 6 days ago - Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026 - Business Wire
- 11 days ago - Exelixis: High-Growth Oncology Name Trading At A Discount - Seeking Alpha
- 20 days ago - Exelixis, Inc. (EXEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 22 days ago - Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 - Business Wire
- 26 days ago - Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer - Business Wire
- 27 days ago - Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026 - Business Wire